Triovance Presents Diabetic Foot Disease Treatment to Investors at INCIDE Pharma & Health Tech Booster Program Demo Day

November 08, 2024 02:20 AM AEDT | By EIN Presswire
 Triovance Presents Diabetic Foot Disease Treatment to Investors at INCIDE Pharma & Health Tech Booster Program Demo Day
Image source: EIN Presswire
MEXICO CITY, MEXICO, November 7, 2024 /EINPresswire.com/ -- Triovance, one of eight private company finalists in the highly competitive INCIDE Pharma & Health Tech Booster Program, will today present its lead therapeutic product, TRV-01, to investors participating in the INCIDE Demo Day. TRV-01 is a genetically engineered skin substitute modified to secrete insulin and VEGF.

INCIDE Presentation Details:
• Blanca Segura, Ph.D., CEO and co-founder of Triovance
• Presentation Title: Powered to CURE Diabetic Foot Disease from Within
• November 7, 2024 at 10:30 AM CST
• Hotel Sofitel City Reforma, Salon Louvre, Mexico City

INCIDE’s Demo Day is attended by prominent venture capital firms and family offices, strategic partners, and industry leaders in the healthcare and technology sectors. Organized by Fundación Incide A.C., the INCIDE Booster Program is an initiative fostering competitiveness, productivity and value creation in science, technology and innovation companies originating in Latin America.

“It’s an honor to have been chosen as a finalist in the INCIDE Booster Program and we look forward to presenting our innovative therapeutic technology to participating investors,” said Blanca Segura, Ph.D., CEO and co-founder of Triovance. “More than 120 million people worldwide suffer from diabetic foot ulcers. In preclinical studies, our lead product, TRV-01, improved tissue regeneration, increased angiogenesis and decreased glycation in diabetic foot ulcers. This is the first technology with the potential to cure diabetic foot ulcers from within as they occur—reducing hospitalizations and amputations, lowering treatment costs, and dramatically improving patient quality of life.”

About Triovance
Triovance is a late-preclinical stage biotechnology company transforming the treatment of diabetic foot disease by curing from within. Its lead product, TRV-01, is an engineered skin substitute, genetically modified to deliver insulin and VEGF directly to wound beds. TRV-01 enhances blood flow and improves cellular regeneration while protecting wounds. A low-cost, non-invasive, scalable solution for outpatient care, it is the only therapeutic treatment technology that cures diabetic foot disease at the source. Visit www.triovance.com or follow us on LinkedIn.

About the INCIDE Booster Program
The INCIDE Pharma & Healthtech Booster by New Genesis is an intensive eight-week program for biotechnology startups, providing tools and insights to raise capital successfully. Through workshops and one-on-one mentoring sessions, participants receive guidance from industry leaders to optimize business models, intellectual property strategies and market assessments.

Media Contact

Katie Morris, Ph.D.
ENTENTE Network
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.